Describe T staging for patients with renal mass + tumor thrombus
Which tool is used to guide first line therapy selection in mRCC?
International mRCC Database Consortium (IMDC) prognostic model
How is oligometastatic RCC defined?
Five or fewer metastatic lesions
What is the difference between tumor thrombus and bland thrombus?
Tumor thrombus is enhancing, vascular, connected to tumor and expands the IVC.
Bland thrombus is avascular, non-enhancing, and treated like a clot (anticoagulation if appropriate).
Demonstrated that first-line Nivolumab + Ipilimumab significantly improved overall survival and response rate compared with Sunitinib in intermediate/poor-risk metastatic RCC.
Checkmate-214
Describe the more technical (Neves Zincke) classification for tumor thrombus
Name the 5 predictors of overall survival included in the MSKCC prognostic Criteria.
Bonus Q not worth making it's own question: What changes make it the IMDC model?
1. KPS <80%
2. Dx of RCC to treatment interval < 1 year
3. Anemia
4. Elevated LDH
5. Hypercalcemia
Bonus q:
Remove elevated LDH, add neutrophilia and thrombocytosis.
Which local therapy is utilized to treat painful bone metastases?
Radiation therapy is preferred for painful bone metastases and lesions threatening spinal stability.
What percentage of renal cell carcinomas present with venous tumor thrombus?
~10%
Showed Pembrolizumab + Axitinib improved PFS, OS, and ORR across all IMDC risk groups versus Sunitinib.
Keynote-426
What do you need to clamp before opening the IVC for thrombectomy, and in what order?
1. Ipsilateral renal artery
2. Infrarenal IVC (below thrombus)
3. Lumbar veins between the clamps
4. Contralateral renal vein
5. Hepatic inflow occlusion — if thrombus above hepatic veins (Level III/IV)
6. Suprarenal / suprahepatic IVC (above thrombus)
What is the most commonly used first-line approach for metastatic RCC today?
Immunotherapy + VEGF-TKI combination therapy
What makes a good candidate for cytoreductive nephrectomy?
Good performance status, clear cell histology without sarcomatoid differentiation, absence of brain/liver/extensive bone mets, ability to debulk most of the tumor with surgery
Which laterality is more often associated with IVC tumor thrombus requiring complex thrombectomy?
Right-sided tumors.
Shorter venous course → easier IVC access → more extension.
Demonstrated Nivolumab + Cabozantinib improved OS, PFS, and quality of life compared with Sunitinib.
Checkmate-9ER
How do you occlude the hepatic inflow for a level III/IV thrombus? What is the technique called?
Pringle maneuver - Clamp portal triad via tourniquet/clamp on hepatoduodenal ligament
Which first-line IO + VEGF-TKI improves OS across all IMDC risk groups?
pembrolizumab + axitinib "axi-pembro"
Supported by the KEYNOTE‑426 trial.
What was the outcome of the 2001 era cytoreductive nephrectomy (CN) trials?
Showed interferon-alpha + CN improved OS by ~6 months vs interferon alone.
What specific anatomy allows you to ligate the IVC in right-sided disease without reconstruction?
Left renal vein appreciable collateral drainage via gonadal, adrenal, lumbar veins.
Showed Nivolumab monotherapy improved overall survival over Everolimus in patients previously treated with VEGF-TKI therapy.
Checkmate-025
You notice that the IVC is completely occluded by tumor thrombus on imaging with extensive collaterals. How do you approach this surgically, if possible?
Remove the involved segment of IVC en bloc with the kidney and thrombus, then reconstruct or ligate the IVC.
What IO/IO regimen showed higher response rates, PFS, and OS vs sunitinib and is recommended for intermediate/poor risk patients.
Nivolumab + ipilimumab
CheckMate‑214 trial (phase III, untreated advanced RCC vs sunitinib).
Describe the CARMENA trial?
Demonstrated sunitinib alone was not inferior to CN → sunitinib in intermediate/poor-risk clear-cell RCC.
What is utilized intra-op to evaluate tumor fragility, clamp placement, and detect real-time embolization.
TEE
Demonstrated Lenvatinib + Pembrolizumab produced significantly higher response rates and PFS compared with Sunitinib in untreated advanced RCC.
CLEAR